Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CN201
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : $1,300.0 million
Deal Type : Acquisition
Merck Puts Up Potential $1.3B to Acquire Curon’s B Cell Depletion Therapy
Details : Under the terms of the agreement, Merck through a subsidiary will acquire full global rights to CN201, which is being evaluated in early-stage for treating acute lymphoblastic leukemia.
Product Name : CN201
Product Type : Large molecule
Upfront Cash : $700.0 million
August 09, 2024
Lead Product(s) : CN201
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : $1,300.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?